sj-docx-1-tan-10.1177_1756286421998915 – Supplemental material for High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

Dwyer, Christopher M.; Jokubaitis, Vilija G.; Stankovich, Jim; Baker, Josephine; Haartsen, Jodi; Butzkueven, Helmut; Cartwright, Adriana; Shuey, Neil; Fragoso, Yara Dadalti; Rath, Louise; Skibina, Olga; Fryer, Kylie; Butler, Ernest; Coleman, Jennifer; MacIntrye, Jennifer; Macdonell, Richard; Walt, Anneke van der

doi:10.25384/SAGE.14443869.v1

sj-docx-1-tan-10.1177_1756286421998915.docx (17.68 kB)

sj-docx-1-tan-10.1177_1756286421998915 – Supplemental material for High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients

journal contribution

posted on 2021-04-17, 12:07 authored by Christopher M. Dwyer, Vilija G. Jokubaitis, Jim Stankovich, Josephine Baker, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Yara Dadalti Fragoso, Louise Rath, Olga Skibina, Kylie Fryer, Ernest Butler, Jennifer Coleman, Jennifer MacIntrye, Richard Macdonell, Anneke van der Walt

Supplemental material, sj-docx-1-tan-10.1177_1756286421998915 for High rates of JCV seroconversion in a large international cohort of natalizumab-treated patients by Christopher M. Dwyer, Vilija G. Jokubaitis, Jim Stankovich, Josephine Baker, Jodi Haartsen, Helmut Butzkueven, Adriana Cartwright, Neil Shuey, Yara Dadalti Fragoso, Louise Rath, Olga Skibina, Kylie Fryer, Ernest Butler, Jennifer Coleman, Jennifer MacIntrye, Richard Macdonell and Anneke van der Walt in Therapeutic Advances in Neurological Disorders